A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Acne Clinical Trial

Official title:

An Open, Multicenter, Phase III Extension Clinical Trial to Evaluate the Long-term Safety of ASC40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne Vulgaris

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06248008
• Other study ID #: ASC40-304
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: April 24, 2024
• Est. completion date: March 9, 2026

Study information

• Verified date: February 2024
• Source: Ascletis Pharmaceuticals Co., Ltd.
• Contact: Xiang Leihong, Doctor
• Phone: 021-52888045
• Email: flora_xiang[@]vip.163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 240
• Est. completion date: March 9, 2026
• Est. primary completion date: October 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Participants who have successfully completed a 12-week Phase III study of ASC40-303;

• Have fully understood this research and voluntarily signed the informed consent;

• The fertile male and female subjects of reproductive age agreed to use effective contraception from the time they signed the informed consent until 3 months after the final administration of the investigationa drug;

• Subjects are willing and able to complete the study, understand and comply with the study requirements, comply with the study requirements restrictions and related education, use the investigational drug as prescribed by the physician, and follow up according to the study schedule.

Exclusion Criteria:

• Discontinue participation in the ASC40-303 Phase III study for any reason;

• Are receiving/planning to receive any systemic acne medications, systemic retinoids, systemic corticosteroids, or any androgen/antiandrogen therapy (e.g., testosterone, spironolactone);

• Pregnant, nursing, or planning a pregnancy during the study period;

• Have major complications (including clinically significant abnormalities in clinical laboratory tests), mental disorders, or other factors deemed unsuitable for study participation by the investigator.

Related Conditions & MeSH terms

• Acne
• Acne Vulgaris

Intervention

Drug:
• ASC40
ASC40 tablets orally once daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ascletis Pharmaceuticals Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and percentage of subjects with treatment emergent adverse events (TEAE)	The number and percentage of all subjects with treatment emergent adverse events (TEAE) from the first dose to 40 weeks of treatment.	From the first dose to 40 weeks of treatment.
Primary	Number and percentage of subjects with serious adverse event (SAE).	Number and percentage of subjects with serious adverse event (SAE) from the first dose to 40 weeks of treatment.	From the first dose to 40 weeks of treatment.
Primary	Number and percentage of subjects who discontinued due to adverse events.	Number and percentage of subjects who discontinued due to adverse events from the first dose to 40 weeks of treatment.	From the first dose to 40 weeks of treatment.
Secondary	At the end of the visit, the number of people whose IGA rating had decreased by at least 2 points from the baseline period of the study.	At the end of the visit, the number of subjects whose IGA rating had decreased by at least 2 points from the baseline period of the study.	up to 40 weeks.
Secondary	At the end of the visit, the number of subjects with an IGA score of 3 or higher at baseline dropped to an IGA score of 0 or 1.	At the end of the visit, the number of subjects with an IGA score of 3 or higher at baseline dropped to an IGA score of 0 or 1 among all subjects.	up to 40 weeks.
Secondary	Percentage change in total skin lesion count at the end of the visit compared to the baseline period of the study.	Percentage change in total skin lesion count at the end of the visit compared to the baseline period of the study.	up to 40 weeks.
Secondary	Percentage change in total inflammatory skin lesion count at the end of the visit compared to the baseline period of the study.	Percentage change in total inflammatory skin lesion count for all subjects at the end of the visit compared to the baseline period of the study.	up to 40 weeks.